Elena Plans-Beriso

Elena Plans-Beriso

Auto-generated profile, based on publicly available information

Elena Plans-Beriso

CIBER of Epidemiology and Public Health (CIBERESP), Avenida Monforte de Lemos Madrid Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
EPE Plans-Beriso
E Plans-Beriso
CBC Babb-De-Villiers
C Babb-De-Villiers
DPD Petrova
D Petrova
CBC Barahona-López
C Barahona-López
PDP Diez-Echave
P Diez-Echave
BPB Pérez-Gómez
B Pérez-Gómez
Introduction: Personalised prevention aims to delay or avoid disease occurrence, progression, and recurrence of disease through the adoption of targeted interventions that consider the individual biological, including genetic data, environmental and behavioural characteristics, as well as the socio-cultural context. This protocol summarises the main features of a rapid scoping review to show the research landscape on biomarkers or a combination of biomarkers that may help to better identify subgroups of individuals with different risks of developing specific diseases in which specific preventive strategies could have an impact on clinical outcomes. This review is part of the “Personalised Prevention Roadmap for the future HEalThcare” (PROPHET) project, which seeks to highlight the gaps in current personalised preventive approaches, in order to develop a Strategic Research and Innovation Agenda for the European Union. Objective: To systematically map and review the evidence of biomarkers that are available or under development in cancer, cardiovascular and neurodegenerative diseases that are or can be used for personalised prevention in the general population, in clinical or public health settings. Methods: Three rapid scoping reviews are being conducted in parallel (February–June 2023), based on a common framework with some adjustments to suit each specific condition (cancer, cardiovascular or neurodegenerative diseases). Medline and Embase will be searched to identify publications between 2020 and 2023. To shorten the time frames, 10% of the papers will undergo screening by two reviewers and only English-language papers will be considered. The following information will be extracted by two reviewers from all the publications selected for inclusion: source type, citation details, country, inclusion/exclusion criteria (population, concept, context, type of evidence source), study methods, and key findings relevant to the review question/s. The selection criteria and the extraction sheet will be pre-tested. Relevant biomarkers for risk prediction and stratification will be recorded. Results will be presented graphically using an evidence map. Inclusion criteria: Population: general adult populations or adults from specific pre-defined high-risk subgroups; concept: all studies focusing on molecular, cellular, physiological, or imaging biomarkers used for individualised primary or secondary prevention of the diseases of interest; context: clinical or public health settings. Systematic review registration: https://doi.org/10.17605/OSF.IO/7JRWD (OSF registration DOI).

10 November 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
EGEsther Garcia-Esquinas
Esther Garcia-Esquinas
ACAdrián Carballo-Casla
Adrián Carballo-Casla
RORosario Ortolá
Rosario Ortolá
MSMercedes Sotos-Prieto
Mercedes Sotos-Prieto
POPablo Olmedo
Pablo Olmedo
FRFernando Rodríguez-Artalejo
Fernando Rodríguez-Artalejo
Background: Selenium is an essential trace element with an antioxidant and anti-inflammatory capacity that has been associated in experimental studies with beneficial effects on appetite control, the regulation of the gut microbiota, and control of the anabolic–catabolic balance. The main aim of the present study was to evaluate the association between circulating selenium concentrations and the risk of developing undernutrition in older adults. Methods: This was a cohort study with 1398 well-nourished community-dwelling individuals aged ≥ 65 years residing in Spain in 2017, who were followed for a mean of 2.3 years. Whole blood selenium was measured at baseline using inductively coupled plasma-mass spectrometry. Undernutrition was assessed at baseline and at follow-up, and defined as having at least one of the three GLIM phenotypic criteria (involuntary weight loss, a low body mass index, and a reduced muscle mass) and at least one of the two etiologic criteria (reduced food consumption or nutrient assimilation and inflammation/disease burden). Results: During the follow-up, 142 participants (11%) developed moderate undernutrition and 113 (8.8%) severe undernutrition. The standardized relative risks of moderate and severe undernutrition at the 75th percentile of Se levels versus the 25th were 0.90 and 0.70, respectively. In dose–response analyses, the risk of severe undernutrition decreased linearly with increasing selenium concentrations. This association was independent of protein intake or diet quality and was stronger among participants with a diagnosis of a musculoskeletal disorder. Conclusions: The results suggest that an adequate dietary selenium status is needed to prevent undernutrition in older adults. Also, this may open the door for clinical trials with selenium supplementation, at doses considered as safe, to prevent undernutrition.

Verified
Journal Article
Open access
PDF file
CVChantal Babb de Villiers
Chantal Babb de Villiers
EPElena Plans-Beriso
Elena Plans-Beriso
CEChaitanya Erady
Chaitanya Erady
LBLaura Blackburn
Laura Blackburn
HWHayley Wilson
Hayley Wilson
MKMark Kroese
Mark Kroese
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality globally. Early detection and personalised prevention strategies are crucial for reducing the burden of CVD. The use of biomarkers plays a pivotal role in identifying individuals at risk and facilitating timely interventions. This rapid scoping review aims to identify and evaluate current research on biomarkers used for primary and secondary personalised prevention of CVD, highlighting evidence gaps and the integration of digital technologies. A comprehensive search was conducted in Medline and Embase databases from January 2020 to February 2023. Joanna Briggs Institute (JBI) Manual for Evidence Synthesis and PRISMA-ScR guidelines were followed. A total of 775 studies were included, with ischemic heart disease (IHD) and stroke being the most investigated CVDs. Molecular, cellular, imaging, physiological, and anthropometric biomarkers were included. Molecular biomarkers, particularly genetic and biochemical, were the most researched. For secondary prevention, there was considerable research using imaging biomarkers. Genetic biomarker research was the most frequent category of biomarker identified, particularly using variant analysis and polygenic scores, followed by biochemical, imaging, and physiological biomarkers. There was also evidence of the integration of artificial intelligence to enhance the predictive capabilities of these biomarkers. Despite progress, research gaps were identified for less common CVDs, such as aortic aneurysm and nonrheumatic valvular heart disease, and limited research investigating other molecular biomarker types, such as epigenetics and transcriptomics.

7 March 2024 in Journal of Epidemiology and Community Health
Verified
Journal Article
Closed access
PDF file
EPElena Plans-Beriso
Elena Plans-Beriso
Pedro GullónPedro Gullón
Pedro Gullón
MFMario Fontan-Vela
Mario Fontan-Vela
MFManuel Franco
Manuel Franco
BPBeatriz Pérez-Gómez
Beatriz Pérez-Gómez
UBUsama Bilal
Usama Bilal
Background: Evidence has shown contradicting results on how the density of urban green spaces may reduce socioeconomic inequalities in type 2 diabetes (equigenic hypothesis). The aim of this study is to test whether socioeconomic inequalities in diabetes prevalence are modified by park density. Methods: We designed a population-wide cross-sectional study of all adults registered in the primary healthcare centres in the city of Madrid, Spain (n=1 305 050). We obtained georeferenced individual-level data from the Primary Care Electronic Health Records, and census-tract level data on socioeconomic status (SES) and park density. We modelled diabetes prevalence using robust Poisson regression models adjusted by age, country of origin, population density and including an interaction term with park density, stratified by gender. We used this model to estimate the Relative Index of Inequality (RII) at different park density levels. Findings: We found an overall RII of 2.90 (95% CI 2.78 to 3.02) and 4.50 (95% CI 4.28 to 4.74) in men and women, respectively, meaning that the prevalence of diabetes was three to four and a half times higher in low SES compared with high SES areas. These inequalities were wider in areas with higher park density for both men and women, with a significant interaction only for women (p=0.008). Interpretation: We found an inverse association between SES and diabetes prevalence in both men and women, with wider inequalities in areas with more parks. Future works should study the mechanisms of these findings, to facilitate the understanding of contextual factors that may mitigate diabetes inequalities.

9 December 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
CBCristina Barahona‐López
Cristina Barahona‐López
EPElena Plans‐Beriso
Elena Plans‐Beriso
PDPaul Diez‐Echave
Paul Diez‐Echave
OHOrlando Hernández
Orlando Hernández
NLNerea Fernández de Larrea
Nerea Fernández de Larrea
BPBeatriz Perez‐Gomez
Beatriz Perez‐Gomez
Neurodegenerative diseases represent a major public health challenge due to their high prevalence and poor prognosis. Identifying biomarkers to stratify individuals by their risk of developing these diseases may help to define new personalized prevention interventions. The objective of this study was to conduct a scoping review of biomarkers for primary and secondary personalized prevention of neurodegenerative diseases. The search targeted biomarkers in adults or high‐risk subpopulations in clinical or public health settings for Alzheimer's disease, vascular dementia, Lewy body disease, frontotemporal dementia, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis. Ultimately, 286 papers were included in the review and the interactive gap map. There is a strong focus on Alzheimer's disease, and most papers included ‐omics‐based biomarkers and/or used artificial intelligence. Genetics/genomics are at the forefront of current scientific research, although there is a notable gap in studying gene–environment interactions, and studies in clinical settings are still scarce. Highlights: Research indicates a strong focus on Alzheimer´s disease and limited research in other diseases. Genetics and genomics are at the forefront of current scientific research. We found biomarkers for predicting progression in mild cognitive decline. There is a notable gap in studying gene‐environment interactions. Studies investigating biomarkers in a clinical context are still scarce.

11 March 2026 in Health Science Reports
Verified
Journal Article
Open access
GSGary Sánchez‐Gordón
Gary Sánchez‐Gordón
EPElena Plans‐Beriso
Elena Plans‐Beriso
CLCristina Barahona López
Cristina Barahona López
BABerta Anta
Berta Anta
Oscar MilletOscar Millet
Oscar Millet
APAdela Castelló Pastor
Adela Castelló Pastor
Background and Aims: Chronic inflammation contributes to various chronic diseases, emphasizing the need for reliable biomarkers for early detection and understanding its causes. Measuring chronic inflammation poses challenges since most biomarkers are influenced by both acute and chronic states and recent exposures. Joint analysis of inflammatory biomarkers may help identify specific biological signatures linked to chronic inflammation. The scoping review whose protocol is described here, aims to map the existing literature identifying these signatures in adults using data reduction methods in epidemiological studies. Methods: The review will follow the Joanna Briggs Institute methodology and the extension for Scoping Reviews of the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis checklist (PRISMA‐ScR). An electronic search will be performed in Medline (via PubMed) and Embase (via Elsevier) for studies published until October 2023, using relevant terms related to inflammation biomarkers, and data reduction methods. Eligible studies include systematic reviews and primary experimental, quasi‐experimental, and observational research analyzing inflammation biomarkers in blood, urine, or saliva from adults. Studies focused on acute infectious diseases, transient inflammatory conditions, and those not published in English or Spanish will be excluded. Four independent reviewers will conduct a two‐phase screening of studies (title/abstract and full‐text), with a third reviewer resolving disagreements. Data extraction will be handled by one reviewer and verified by another using a predefined form. Results: Findings will be summarized in a PRISMA flowchart. Interactive visual maps will illustrate the identified inflammatory signatures, categorized by study design, data reduction method, population type, and clinical condition. All resources will be publicly available. Conclusion: This review will provide a comprehensive overview of inflammation biomarker signatures derived from data reduction methods while identifying existing knowledge gaps in the field. Scoping Review Registration: This protocol was registered on January 25, 2024, on Open Science Framework ( https://doi.org/10.17605/OSF.IO/85XUF ).